Log In
Print
BCIQ
Print
Print this Print this
 

BL-8030 (formerly GNS-227)

  Manage Alerts
Collapse Summary General Information
Company Genoscience Pharma
DescriptionSelective HCV NS3/4A inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat hepatitis C virus (HCV)
Regulatory Designation
Partner BioLineRx Ltd.; Jiangsu Chia-Tai Tianqing Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$30.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today